Latest Breaking News On - தரநிலை பரிசோதனை - Page 1 : comparemela.com
Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.
Covid Test Kit Maker Set for Seoul Debut at $4 7 Billion Value
bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Korean Covid-19 Test Maker Prepares For IPO Amid Revenue Leap, Founder To Become Billionaire
Share to Facebook
COURTESY OF SD Biosensor
Cho Young-sik, founder of Covid-19 test maker SD Biosensor, is set to become a billionaire this month, when the South Korean company is expected to list its shares on the Korea Exchange.
SD Biosensor is offering 12.4 million shares at a price range of 45,000 won to 52,000 won apiece. At the midpoint of that range, the deal could raise 603 billion won (about $530 million) and value the company at 4.9 trillion won. The subscription period is to start July 8 and end July 9. The company says it plans to use the proceeds to expand production lines, diversify its product portfolio and expand its presence in Europe and South America.
Gold Standard Diagnostics (GSD) recently announced FDA clearance of a new B. burgdorferi IgG/IgM VlsE-OspC EIA test. This test, when used in conjunction with the other FDA cleared GSD Lyme EIA tests can be used in the CDC recommended modified two-tiered testing (MTTT) algorithm.
Borrelia burgdorferi spirochetes/CDC
In 2014, the CDC issued an updated recommendation for the serologic diagnosis of Lyme disease, endorsing the use of a two-tier testing algorithm that uses a second enzyme immunoassay, or EIA, in place of a western immunoblot assay.
Gold Standard Diagnostics now offers a solution for this Lyme testing algorithm, which complements GSD’s existing market-leading Lyme test portfolio. With the addition of the B. burgdorferi IgG/IgM VlsE-OspC EIA test, customers can choose which tests and algorithms best meet their laboratory and client’s needs. All six assays are designed for optimal performance and can be run on any open automation platform.
Isothermal Nucleic Acid Amplification Technology Industry Trends Include Incorporation Of Nanostructures
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.